BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Nalbandian, A., Sehgal, K., Gupta, A., & others. (2021). Post-acute COVID-19 syndrome. Nature Medicine, 1–15. Added by: Dr. Enrique Feoli (23/03/2021, 20:16) Last edited by: Dr. Enrique Feoli (23/03/2021, 20:17) |
 |
| Resource type: Journal Article DOI: 10.1038/s41591-021-01283-z ID no. (ISBN etc.): 1546-170X BibTeX citation key: Nalbandian2021 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: COVID-19 Creators: Gupta, Nalbandian, others, Sehgal Collection: Nature Medicine |
Views: 1/228
|
| Abstract |
|
{Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.}
|